Chemicals · Founded 1988 · www.balajiamines.com · BSE 530999 · NSE BALAJI AMINE · ISIN INE050E01027
No Notes Added Yet
Business
Balaji Amines Ltd. is a leading Indian manufacturer of aliphatic amines and their derivatives. The company's core business involves producing various methylamines, ethylamines, specialty chemicals, and pharma intermediates. These products serve diverse end-user industries, including pharmaceuticals, agrochemicals, rubber chemicals, water treatment chemicals, and solvents. Balaji Amines primarily makes money by manufacturing and selling these chemical compounds to industrial clients, often through long-term supply agreements and spot market sales.
Revenue Mix
The company's primary revenue streams are derived from:
Amines: This segment includes various methylamines and ethylamines, which are basic building blocks for many other chemicals.
Specialty Chemicals & Derivatives: This segment comprises more complex amines and their derivatives tailored for specific applications, as well as pharmaceutical intermediates.
While specific percentage contributions can fluctuate and are not always explicitly broken down by the company for individual products, amines and their derivatives constitute the vast majority of the company's revenue. The company also has a small hospitality segment which is not material to its core chemical business.
Industry
Balaji Amines operates within the Indian specialty chemicals industry, which is characterized by growth driven by increasing domestic demand and global supply chain shifts. The amines market is a niche but critical component of this industry. Balaji Amines holds a strong position as one of the largest manufacturers of aliphatic amines in India. It competes with other domestic players and faces competition from imports, but its scale and product range give it a prominent standing. The industry generally requires significant capital expenditure and adherence to environmental regulations.
MOAT
Backward Integration: Balaji Amines has undertaken significant backward integration for key raw materials like Methylamines and DMF, which helps in cost control, ensures raw material security, and reduces exposure to price volatility of these inputs.
Diversified Product Portfolio: The company produces a wide range of amines and specialty chemicals, catering to multiple industries, which diversifies revenue streams and reduces dependence on any single product or sector.
Established Relationships & Scale: As a long-standing and large producer, it has established strong relationships with customers across various industries and benefits from economies of scale in manufacturing.
Process Expertise: Developing and refining the chemical processes for amine production requires significant technical expertise and operational experience, creating a barrier to entry for new players.
Growth Drivers
Demand from End-User Industries: Continued growth in the pharmaceutical, agrochemical, and rubber industries in India and globally will drive demand for amines and specialty chemicals.
Import Substitution: Government initiatives and a push towards domestic manufacturing (e.g., "Make in India") could encourage import substitution, benefiting local manufacturers like Balaji Amines.
Capacity Expansion: The company's ongoing capital expenditure projects to expand existing capacities and introduce new products are expected to drive volume growth.
New Product Development: Introduction of higher-value specialty chemicals and pharmaceutical intermediates can improve realizations and margins.
China+1 Strategy: Global companies seeking to diversify their supply chains away from China may look to Indian manufacturers, including Balaji Amines.
Risks
Raw Material Price Volatility: The profitability of Balaji Amines is sensitive to fluctuations in the prices of key raw materials like methanol, ammonia, and acetic acid, which are derivatives of crude oil and natural gas.
Environmental & Regulatory Risks: The chemical industry is subject to stringent environmental regulations. Any changes in these regulations or non-compliance could lead to operational disruptions, penalties, or increased costs.
Cyclicality of End-User Industries: Downturns in key end-user sectors like pharmaceuticals or agrochemicals could impact demand for the company's products.
Competition: Intense competition from domestic and international players, including potential new entrants, could put pressure on pricing and margins.
Capex Execution Risk: Delays or cost overruns in ongoing and planned capacity expansion projects could impact future growth projections and financial performance.
Management & Ownership
Balaji Amines is primarily a promoter-driven company, led by the Reddy family. The promoters hold a significant stake in the company, which is common in Indian businesses, indicating strong alignment with shareholder interests. The management team has extensive experience in the chemical industry, particularly in the production of amines and specialty chemicals. The ownership structure generally features a high promoter holding, with the remaining shares held by institutional investors, retail investors, and other entities.
Outlook
Balaji Amines is positioned in a growing segment of the Indian chemical industry, driven by strong demand from domestic and international end-user markets. Its backward integration and diversified product portfolio provide a degree of resilience against market fluctuations and competitive pressures. Planned capacity expansions and focus on specialty chemicals offer a clear path for future growth. However, the company faces inherent risks associated with raw material price volatility, intense competition, and the cyclical nature of its customer industries. Successful execution of expansion plans, effective cost management, and navigating regulatory landscapes will be key to sustaining its growth trajectory and profitability in the coming years.
Price goes above X
Price falls below X
PE goes above X
PE falls below X
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 414 | 385 | 347 | 313 | 353 | 358 | 341 | 331 | 395 | 456 |
| Other Income | 9 | 8 | 9 | 8 | 8 | 9 | 7 | 5 | 8 | 6 |
| Total Income | 423 | 393 | 356 | 321 | 361 | 367 | 348 | 336 | 403 | 461 |
| Total Expenditure | 316 | 319 | 286 | 267 | 293 | 304 | 281 | 275 | 301 | 340 |
| Operating Profit | 106 | 74 | 70 | 54 | 68 | 64 | 67 | 62 | 102 | 121 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 |
| Depreciation | 12 | 12 | 12 | 12 | 13 | 14 | 14 | 14 | 14 | 14 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 93 | 62 | 57 | 41 | 54 | 49 | 52 | 46 | 86 | 106 |
| Provision for Tax | 20 | 16 | 15 | 10 | 13 | 12 | 15 | 15 | 21 | 28 |
| Profit After Tax | 72 | 46 | 41 | 31 | 40 | 37 | 37 | 31 | 65 | 78 |
| Adjustments | -4 | -2 | -0 | 2 | -0 | 1 | -3 | 1 | -2 | -3 |
| Profit After Adjustments | 68 | 43 | 41 | 33 | 40 | 38 | 35 | 31 | 63 | 75 |
| Adjusted Earnings Per Share | 21 | 13.4 | 12.6 | 10.2 | 12.4 | 11.7 | 10.7 | 9.7 | 19.5 | 23.1 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 643 | 670 | 861 | 943 | 936 | 1311 | 2323 | 2355 | 1642 | 1397 | 1425 | 1523 |
| Other Income | 6 | 9 | 12 | 6 | 8 | 11 | 15 | 15 | 30 | 33 | 29 | 26 |
| Total Income | 649 | 679 | 873 | 949 | 944 | 1323 | 2338 | 2371 | 1671 | 1430 | 1454 | 1548 |
| Total Expenditure | 520 | 521 | 679 | 751 | 758 | 944 | 1700 | 1746 | 1318 | 1165 | 1160 | 1197 |
| Operating Profit | 129 | 158 | 194 | 198 | 186 | 379 | 637 | 624 | 353 | 265 | 294 | 352 |
| Interest | 22 | 13 | 9 | 13 | 23 | 18 | 17 | 12 | 6 | 4 | 5 | 6 |
| Depreciation | 19 | 20 | 19 | 20 | 32 | 34 | 42 | 46 | 45 | 48 | 56 | 56 |
| Exceptional Income / Expenses | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 88 | 126 | 166 | 165 | 131 | 327 | 578 | 567 | 302 | 213 | 232 | 290 |
| Provision for Tax | 30 | 43 | 53 | 48 | 34 | 83 | 160 | 161 | 69 | 55 | 63 | 79 |
| Profit After Tax | 58 | 82 | 113 | 117 | 97 | 243 | 418 | 406 | 232 | 159 | 169 | 211 |
| Adjustments | 0 | 0 | 0 | 0 | 7 | -5 | -49 | -80 | -27 | -1 | -2 | -7 |
| Profit After Adjustments | 58 | 82 | 113 | 118 | 105 | 238 | 368 | 326 | 205 | 158 | 167 | 204 |
| Adjusted Earnings Per Share | 17.8 | 25.4 | 34.9 | 36.3 | 32.3 | 73.5 | 113.7 | 100.5 | 63.2 | 48.6 | 51.6 | 63 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 2% | -15% | 2% | 8% |
| Operating Profit CAGR | 11% | -22% | -5% | 9% |
| PAT CAGR | 6% | -25% | -7% | 11% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 46% | -2% | -15% | 21% |
| ROE Average | 9% | 11% | 20% | 22% |
| ROCE Average | 12% | 14% | 26% | 27% |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 278 | 362 | 467 | 574 | 658 | 894 | 1250 | 1554 | 1722 | 1845 | 1976 |
| Minority's Interest | 2 | 0 | 18 | 18 | 10 | 16 | 65 | 144 | 171 | 173 | 175 |
| Borrowings | 46 | 17 | 42 | 83 | 120 | 89 | 58 | 30 | 11 | 2 | 65 |
| Other Non-Current Liabilities | 63 | 57 | 64 | 62 | 60 | 69 | 72 | 85 | 94 | 102 | 124 |
| Total Current Liabilities | 216 | 199 | 257 | 308 | 264 | 243 | 301 | 149 | 149 | 130 | 402 |
| Total Liabilities | 605 | 635 | 848 | 1046 | 1113 | 1310 | 1745 | 1963 | 2146 | 2252 | 2743 |
| Fixed Assets | 341 | 325 | 316 | 320 | 573 | 543 | 676 | 775 | 891 | 998 | 1038 |
| Other Non-Current Assets | 19 | 30 | 177 | 276 | 79 | 190 | 162 | 155 | 258 | 313 | 764 |
| Total Current Assets | 245 | 280 | 355 | 449 | 461 | 577 | 907 | 1032 | 997 | 941 | 941 |
| Total Assets | 605 | 635 | 848 | 1046 | 1113 | 1310 | 1745 | 1963 | 2146 | 2252 | 2743 |
| #(Fig in Cr.) | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 7 | 9 | 3 | 24 | 20 | 9 | 17 | 33 | 96 | 81 | 149 |
| Cash Flow from Operating Activities | 85 | 60 | 140 | 94 | 144 | 110 | 220 | 354 | 334 | 255 | 184 |
| Cash Flow from Investing Activities | -29 | -10 | -135 | -119 | -130 | -62 | -147 | -210 | -274 | -139 | -344 |
| Cash Flow from Financing Activities | -54 | -55 | 16 | 21 | -26 | -37 | -57 | -81 | -75 | -49 | 85 |
| Net Cash Inflow / Outflow | 2 | -5 | 21 | -4 | -12 | 11 | 16 | 63 | -15 | 68 | -75 |
| Closing Cash & Cash Equivalent | 9 | 3 | 24 | 20 | 9 | 20 | 33 | 96 | 81 | 149 | 74 |
| # | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 17.78 | 25.42 | 34.93 | 36.27 | 32.34 | 73.51 | 113.71 | 100.47 | 63.22 | 48.62 | 51.6 |
| CEPS(Rs) | 23.76 | 31.5 | 40.88 | 42.17 | 39.84 | 85.77 | 141.94 | 139.27 | 85.7 | 63.9 | 69.61 |
| DPS(Rs) | 2 | 2.2 | 2.6 | 2.8 | 3.2 | 4 | 6 | 10 | 11 | 11 | 11 |
| Book NAV/Share(Rs) | 85.87 | 111.87 | 143.99 | 177.13 | 202.99 | 275.94 | 385.74 | 479.69 | 531.42 | 569.44 | 610 |
| Core EBITDA Margin(%) | 17.66 | 20.41 | 20.81 | 20.31 | 18.97 | 28.06 | 26.77 | 25.82 | 19.71 | 16.57 | 18.57 |
| EBIT Margin(%) | 15.77 | 18.98 | 20 | 18.88 | 16.47 | 26.3 | 25.59 | 24.53 | 18.75 | 15.49 | 16.64 |
| Pre Tax Margin(%) | 12.6 | 17.2 | 18.96 | 17.5 | 14.01 | 24.9 | 24.86 | 24.02 | 18.36 | 15.22 | 16.27 |
| PAT Margin (%) | 8.25 | 11.27 | 12.94 | 12.42 | 10.42 | 18.57 | 17.96 | 17.19 | 14.14 | 11.32 | 11.84 |
| Cash Profit Margin (%) | 11.03 | 13.97 | 15.15 | 14.49 | 13.8 | 21.19 | 19.77 | 19.13 | 16.91 | 14.78 | 15.78 |
| ROA(%) | 9.39 | 13.29 | 15.27 | 12.37 | 9.03 | 20.1 | 27.35 | 21.88 | 11.31 | 7.21 | 6.77 |
| ROE(%) | 22.77 | 25.71 | 27.31 | 22.51 | 15.83 | 31.38 | 38.98 | 28.94 | 14.18 | 8.89 | 8.85 |
| ROCE(%) | 23.56 | 30.19 | 32.21 | 25.09 | 17.94 | 35.58 | 50.21 | 39.08 | 18.37 | 12.06 | 12 |
| Receivable days | 63.7 | 62.11 | 61.97 | 65.78 | 73.07 | 71.4 | 70.12 | 74.72 | 77.47 | 77.48 | 79.32 |
| Inventory Days | 49.77 | 44.22 | 39.25 | 48.82 | 53.04 | 30.44 | 26.07 | 40.62 | 65.52 | 73.05 | 66.52 |
| Payable days | 49.2 | 53.28 | 48.49 | 55.56 | 51.29 | 39.43 | 38.47 | 35.6 | 28.27 | 34.34 | 35.34 |
| PER(x) | 10.04 | 14.94 | 16.11 | 13.48 | 7.76 | 23.98 | 25.52 | 19.34 | 32.33 | 24.83 | 18.93 |
| Price/Book(x) | 2.08 | 3.39 | 3.91 | 2.76 | 1.24 | 6.39 | 7.52 | 4.05 | 3.85 | 2.12 | 1.6 |
| Dividend Yield(%) | 1.12 | 0.58 | 0.46 | 0.57 | 1.28 | 0.23 | 0.21 | 0.51 | 0.54 | 0.91 | 1.13 |
| EV/Net Sales(x) | 1.15 | 1.99 | 2.27 | 1.9 | 1.14 | 4.44 | 4.07 | 2.6 | 3.84 | 2.55 | 2.12 |
| EV/Core EBITDA(x) | 5.73 | 8.45 | 10.08 | 9.07 | 5.73 | 15.34 | 14.83 | 9.8 | 17.83 | 13.45 | 10.29 |
| Net Sales Growth(%) | 3.94 | 4.25 | 28.45 | 9.5 | -0.77 | 40.15 | 77.12 | 1.4 | -30.31 | -14.89 | 2 |
| EBIT Growth(%) | 28.12 | 25.9 | 26.15 | 1.83 | -13.45 | 123.75 | 72.63 | -2.79 | -46.79 | -29.57 | 9.65 |
| PAT Growth(%) | 73.55 | 42.94 | 37.44 | 3.45 | -16.76 | 149.82 | 71.63 | -2.92 | -42.74 | -31.73 | 6.66 |
| EPS Growth(%) | 68.11 | 42.94 | 37.44 | 3.85 | -10.84 | 127.29 | 54.67 | -11.64 | -37.07 | -23.11 | 6.14 |
| Debt/Equity(x) | 0.62 | 0.29 | 0.33 | 0.4 | 0.39 | 0.14 | 0.08 | 0.04 | 0.01 | 0.01 | 0.07 |
| Current Ratio(x) | 1.14 | 1.4 | 1.38 | 1.46 | 1.74 | 2.38 | 3.02 | 6.91 | 6.7 | 7.26 | 2.34 |
| Quick Ratio(x) | 0.78 | 0.91 | 1.03 | 0.93 | 1.33 | 1.92 | 2.28 | 4.89 | 4.78 | 5.14 | 1.73 |
| Interest Cover(x) | 4.97 | 10.72 | 19.34 | 13.67 | 6.69 | 18.85 | 34.82 | 48.35 | 47.81 | 58.66 | 44.29 |
| Total Debt/Mcap(x) | 0.3 | 0.09 | 0.08 | 0.14 | 0.32 | 0.02 | 0.01 | 0.01 | 0 | 0 | 0.04 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.7 | 53.7 | 53.7 | 53.7 | 54.62 | 54.59 | 54.59 | 54.59 | 54.59 | 54.56 |
| FII | 4.92 | 5.05 | 5.27 | 5.16 | 5.08 | 5 | 4.52 | 3.3 | 2.98 | 3.17 |
| DII | 1.48 | 1.59 | 1.79 | 1.66 | 1.48 | 1.47 | 1.52 | 1.53 | 1.46 | 1.58 |
| Public | 39.9 | 39.67 | 39.24 | 39.48 | 38.82 | 38.95 | 39.37 | 40.58 | 40.97 | 40.69 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.74 | 1.74 | 1.74 | 1.74 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
| FII | 0.16 | 0.16 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.11 | 0.1 | 0.1 |
| DII | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Public | 1.29 | 1.29 | 1.27 | 1.28 | 1.26 | 1.26 | 1.28 | 1.31 | 1.33 | 1.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | +2% | -15% | +2% | +8% |
| Operating Profit CAGR | +11% | -22% | -5% | +9% |
| PAT CAGR | +6% | -25% | -7% | +11% |
| Share Price CAGR | +46% | -2% | -15% | +21% |
| ROE Average | +9% | +11% | +20% | +22% |
| ROCE Average | +12% | +14% | +26% | +27% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 53.7 | 53.7 | 53.7 | 53.7 | 54.62 | 54.59 | 54.59 | 54.59 | 54.59 | 54.56 |
| FII | 4.92 | 5.05 | 5.27 | 5.16 | 5.08 | 5 | 4.52 | 3.3 | 2.98 | 3.17 |
| DII | 1.48 | 1.59 | 1.79 | 1.66 | 1.48 | 1.47 | 1.52 | 1.53 | 1.46 | 1.58 |
| Public | 39.9 | 39.67 | 39.24 | 39.48 | 38.82 | 38.95 | 39.37 | 40.58 | 40.97 | 40.69 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 1.74 | 1.74 | 1.74 | 1.74 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 | 1.77 |
| FII | 0.16 | 0.16 | 0.17 | 0.17 | 0.16 | 0.16 | 0.15 | 0.11 | 0.1 | 0.1 |
| DII | 0.05 | 0.05 | 0.06 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Public | 1.29 | 1.29 | 1.27 | 1.28 | 1.26 | 1.26 | 1.28 | 1.31 | 1.33 | 1.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 | 3.24 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.